4th International RASopathies Symposium, July 17-19, 2015, Seattle, WA
Co-Chairs
- David Stevenson, MD, Stanford University, CA
- Brigitte Widemann, MD, National Cancer Institute, Bethesda, MD
Speakers and Moderators
| Rosemary Anderson, President NF Michigan, Grand Rapids, MI, USA |
Advocates’ Panel |
| Brage Andresen, PhD University of S. Denmark, Odense, Denmark |
Alternative Splicing Therapeutics – HRAS |
| Annette Bakker, PhD Children’s Tumor Foundation, NY, USA |
Co-Moderator, Collaborations, Industry, and Funding; Business Model |
| Pinar Bayrak-Toydemir, MD, PhD University of Utah, Salt Lake City, UT, USA |
RASA 1 |
| Tammy Bowers, Advocate NSML/LEOPARD syndrome, UT, USA |
Co-Moderator, Advocates’ Panel |
| Emma Burkitt-Wright, MBChB St. Mary’s Hospital, Manchester, UK |
Co-Moderator, Clinical Trails in RASopathies: Design, Endpoints, and Results |
| Kathryn Chatfield, MD, PhD University of Colorado, Denver, CO, USA |
Cardiac Manifestations |
| Judy Doyle, Board Member CFC International, Media, OH, USA |
Advocates’ Panel |
| Florent Elefteriou, PhD Vanderbilt University, Nashville, TN, USA |
Co-Moderator, Preclinical Studies |
| Ype Elgersma, PhD Erasmus University Medical Center, Rotterdam, The Netherlands |
Cognition/Learning |
| Michelle Ellis, Director Noonan UK, London, UK |
Advocates’ Panel |
| Michael Fisher, MD Children’s Hospital Philadelphia, PA, USA |
Agents Targeting RAS/MAPK in Clinical Development: Current Status |
| David Franz, MD Cincinnati Children’s Hospital, OH, USA |
TSC |
| Bruce Gelb, MD Mt. Sinai School of Medicine, New York, NY, USA |
Drug Target Screening – Drosophila |
| Anne Goriely, PhD University of Oxford, UK |
Co-Moderator, Preclinical Studies |
| Karen Gripp, MD A.I.duPont Hospital for Children, Wilmington, DE, USA |
Co-Moderator, Abstracts by Young Investigators |
| Rick Guidotti Positive Exposure |
Photo shoot (Saturday) 2015 Symposium RASopathies Photography (Sunday) |
| Antonio Hardan, MD Stanford University, Stanford, CA, USA |
PTEN |
| Marguerite Hutchinson, JD Plexxicon, Berkeley, CA, USA |
Panelist, Collaborations, Industry, and Funding |
| Kim Keppler-Noreuil, MD National Human Genome Research Institute, Bethesda, MD, USA |
PIK3CA Conditions |
| Bronwyn Kerr, MD University of Manchester, UK |
Co-Moderator, RASopathy Phenotypes (Shared and Discordant) |
| Bruce Korf, MD, PhD University of Alabama, Birmingham, AL, USA |
Cancer |
| Chiara Leoni, MD Università Cattolica Sacro Cuore, Rome, Italy |
Co-Moderator, RASopathy Phenotypes (Shared and Discordant) |
| Ram Mandalam, President and CEO Cellerant, San Carlos, CA, USA |
Panelist, Collaborations, Industry, and Funding |
| Andre Marozsan, Interim Director, Pre-Clinical Pharmacology Alexion, Cheshire, CT, USA |
Panelist, Collaborations, Industry, and Funding |
| Frank McCormick, PhD, FRS, DSc (Hon) University of California, San Francisco, CA, USA |
Keynote Speaker |
| Rene Pierpont, PhD University of Minnesota, Minneapolis, USA |
Post-Symposium Noonan Syndrome Meeting |
| Scott Plotkin, MD, PhD Massachusetts General Hospital, Boston, MA, USA |
Co-Moderator, Clinical rails in RASopathies: Design, Endpoints, and Results; Trial Design Using Individualized Endpoints |
| Katherine A. Rauen University of California at Davis, CA, USA |
MEK Inhibitors for Strength |
| Karlyne Reilly, PhD National Cancer Institute, Bethesda, MD, USA |
NF1 Preclinical Models and Trials |
| Amy Roberts, MD Children’s Hospital Boston, MA, USA |
TRND Study; Co-Moderator, Abstracts by Young Investigators |
| Abby Sandler, PhD National Cancer Institute, Bethesda, MD, USA |
NCI Rare Disease Initiative |
| Lisa Schill, BS RASopathies Network USA, Williamstown, NJ, USA |
Co-PI; Co-Moderator, Collaborations, Industry, and Funding |
| Lisa Schoyer, MFA RASopathies Network USA, Altadena, CA |
PI; Co-Moderator, Advocates’ Panel |
| Suzanne Schrandt, JD Patient-Centered Outcomes Research Institute (PCORI), Washington, DC |
PCORI: Engaging Patients Across the Research Continuum |
| Dawn Siegel, MD Children’s Hospital of Wisconsin, Milwaukee, WI, USA |
Moderator, RASopathies Cousins |
| Alison Silva, EVP & COO Synlogic, Cambridge, MA, USA |
Panelist, Collaborations, Industry, and Funding |
| Patroula Smpokou, MD Children’s National Health System, Washington, DC, USA |
Post-Symposium Noonan Syndrome Meeting |
| David Stevenson, MD Stanford University, Stanford, CA, USA |
Symposium Co-Chair; Overview of the RASopathies |
| Angelica Thomas, Board Member Costello Syndrome Family Network, Austin, TX, USA |
Advocates’ Panel |
| Karin Walsh, PsyD Children’s National Medical Center, WDC, USA |
Pilot Trial of Effect of RAS/MAPK inhibitors on Neurocognitive Function in NF1 |
| Brigitte Widemann, MD National Cancer Institute, Bethesda, MD, USA |
Symposium Co-Chair; Phase 1 Trial of AZD6244 in NF1 Tumo |
